Patents by Inventor Anthony James Taylor
Anthony James Taylor has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20210067544Abstract: An embodiment of a feedback-based system and methods are disclosed for real-time mitigation of fraud and otherwise invalid traffic in a mobile ad environment. The system of three complementary facets of one embodiment comprises four major sub-systems: prevention, detection, control and reporting, which work in cohesion with one another to achieve the common goal of the system. In the embodiment, deterministic and probabilistic methods are applied across all levels of user engagement (impressions, clicks, installs, post-install events, and conversions) to detect the likely sources of invalid traffic and block them in real time. A distinctive and unifying feature of the embodiment of the system is the feedback loop that connects advanced analytics and machine learning techniques that the detection subsystem employs at all levels of user engagement to the real-time blocking mechanism of the prevention subsystem that operates at the initial levels of user engagements, such as clicks and impressions.Type: ApplicationFiled: April 17, 2019Publication date: March 4, 2021Inventors: Luke Anthony James Taylor, Raigon Jolly, André Bonkowski, Andrey Kostenko
-
Patent number: 7828150Abstract: There is provided a container for a medicament powder formed from a material comprising a desiccant. In one embodiment the container is a medicament dispenser comprising a body defining a reservoir for medicament in powder form, and an outlet in communication with said reservoir. In another embodiment the container is a medicament dispenser comprising a body defining a chamber for receipt of a medicament carrier, and an outlet in communication with said chamber. Methods of controlling moisture flow are also described.Type: GrantFiled: June 5, 2001Date of Patent: November 9, 2010Assignee: GlaxoSmithKline LLCInventors: Anthony James Taylor, Michael Harry Golden
-
Publication number: 20090188491Abstract: This invention relates to aerosol formulations of use for the administration of medicaments by inhalation, in particular a pharmaceutical aerosol formulation which comprises particulate salbutamol and physiologically acceptable salts and solvates thereof and a fluorocarbon or hydrogen-containing chlorofluorocarbon propellant, which formulation is substantially free of surfactant. A method of treating respiratory disorders which comprises administration by inhalation of an effective amount of a pharmaceutical aerosol formulation as defined is also described.Type: ApplicationFiled: January 16, 2009Publication date: July 30, 2009Applicant: Glaxo Group LimitedInventors: Rachel Ann Akehurst, Anthony James Taylor, David Andrew Wyatt
-
Patent number: 7498020Abstract: This invention relates to aerosol formulations of use for the administration of medicaments by inhalation, in particular a pharmaceutical aerosol formulation which comprises particulate salbutamol and physiologically acceptable salts and solvates thereof and a fluorocarbon or hydrogen-containing chlorofluorocarbon propellant, which formulation is substantially free of surfactant. A method of treating respiratory disorders which comprises administration by inhalation of an effective amount of a pharmaceutical aerosol formulation as defined is also described.Type: GrantFiled: November 23, 2004Date of Patent: March 3, 2009Assignee: Glaxo Group LimitedInventors: Rachel Ann Akehurst, Anthony James Taylor, David Andrew Wyatt
-
Patent number: 7077129Abstract: There is provided a dispenser comprising a body for receipt of a carrier for a composition; an exit channel definable by the body for passage of the composition to a user; a cover for the exit channel reversibly movable between a storage position in which the cover fully protects the exit channel, to an in-use position wherein the exit channel is exposed. Biasing means act on the cover when the cover is not in the in-use or storage positions, to bias the cover towards either the in-use position or the storage position.Type: GrantFiled: December 18, 2000Date of Patent: July 18, 2006Assignee: Glaxo Group LimitedInventors: Gregor John McLennan Anderson, Anthony James Taylor
-
Patent number: 6919069Abstract: A pharmaceutical aerosol formulation comprising (i) particulate medicament, (ii) 1,1,1,2-tetrafluoroethane, 1,1,1,2,3,3,3,-heptafluoro-n-propane or a mixture thereof as propellant, and (iii) 0.01 to 5% w/w based upon the propellant of a polar cosolvent, the particulate medicament being present in an amount from 0.005% to 5% w/w relative to the total weight of the formulation and having a particle size of less than 100 microns, and which formulation contains less than 0.0001% w/w surfactant based upon the weight of medicament.Type: GrantFiled: April 30, 2003Date of Patent: July 19, 2005Assignee: Glaxo Group LimitedInventors: Rachel Ann Akehurst, Anthony James Taylor, David Andrew Wyatt
-
Patent number: 6893628Abstract: A pharmaceutical formulation comprising (i) one or more particulate medicaments, and (ii) 1,1,1,2-tetrafuoroethane as propellant, which formulation contains less than 0.0001% w/w surfactant based upon the weight of medicament, particulate medicament being present in an amount from 00005 to 5% w/w relative to the total weight of the formulation and having a particle size of less than 100 microns, with the proviso that the medicament is other than salmeterol, salbutamol, fluticasone propionate, beclomethasone dipropionate or a physiologically acceptable salt or solvate thereof and with the proviso that when the formulation consists of betamethasone, ergotamine tartrate or sodium cromoglycate and 1,1,1,2-tetrafluoroethane the weight to weight ratio of medicament to propellant is other than 69:7900 or 0.866% w/w.Type: GrantFiled: March 31, 2003Date of Patent: May 17, 2005Assignee: Glaxo Group LimitedInventors: Rachel Ann Akehurst, Anthony James Taylor, David Andrew Wyatt
-
Publication number: 20040136918Abstract: The present invention is concerned with pharmaceutical formulations comprising a combination of R-salmeterol and flucticasone propionate and the use of such formulations in medicine, particularly in the prophylaxis and treatment of respiratory diseases.Type: ApplicationFiled: March 9, 2004Publication date: July 15, 2004Inventors: Ronique Nichele Garrett, Paul Johnson, Anthony James Taylor
-
Publication number: 20040136920Abstract: This invention relates to aerosol formulations of use for the administration of medicaments by inhalation, in particular a pharmaceutical aerosol formulation which comprises particulate salbutamol and physiologically acceptable salts and solvates thereof and a fluorocarbon or hydrogen-containing chlorofluorocarbon propellant, which formulation is substantially free of surfactant. A method of treating respiratory disorders which comprises administration by inhalation of an effective amount of a pharmaceutical aerosol formulation as defined is also described.Type: ApplicationFiled: December 19, 2003Publication date: July 15, 2004Applicant: Glaxo Group LimitedInventors: Rachel Ann Akehurst, Anthony James Taylor, David Andrew Wyatt
-
Publication number: 20030198600Abstract: A pharmaceutical aerosol formulation comprising (i) particulate medicament, (ii) 1,1,1,2-tetrafluoroethane, 1,1,1,2,3,3,3,-heptafluoro-n-propane or a mixture thereof as propellant, and (iii) 0.01 to 5% w/w based upon the propellant of a polar cosolvent, the particulate medicament being present in an amount from 0.005% to 5% w/w relative to the total weight of the formulation and having a particle size of less than 100 microns, and which formulation contains less than 0.0001% w/w surfactant based upon the weight of medicament.Type: ApplicationFiled: April 30, 2003Publication date: October 23, 2003Applicant: Glaxo Group LimitedInventors: Rachel Ann Akehurst, Anthony James Taylor, David Andrew Wyatt
-
Publication number: 20030165437Abstract: A pharmaceutical formulation comprising (i) one or more particulate medicaments, and (ii) 1,1,1,2-tetrafuoroethane as propellant, which formulation contains less than 0.0001% w/w surfactant based upon the weight of medicament, particulate medicament being present in an amount from 00005 to 5% w/w relative to the total weight of the formulation and having a particle size of less than 100 micrions, with the proviso that said medicament is other than salmeterol, salbutamol, fluticasone propionate, beclomethasone dipropionate or a physiologically acceptable salt or solvate thereof and with the proviso that when said formulation consists of betamethasone, ergotamine tartrate or sodium cromoglycate and 1,1,1,2-tetrafluoroethane the weight to weight ratio of medicament to propellant is other than 69:7900 or 0.866% w/w.Type: ApplicationFiled: March 31, 2003Publication date: September 4, 2003Applicant: Glaxo Group LimitedInventors: Rachel Ann Akehurst, Anthony James Taylor, David Andrew Wyatt
-
Publication number: 20030140923Abstract: There is provided a container for a medicament powder formed from a material comprising a desiccant. In one embodiment the container is a medicament dispenser comprising a body defining a reservoir for medicament in powder form, and an outlet in communication with said reservoir. In another embodiment the container is a medicament dispenser comprising a body defining a chamber for receipt of a medicament carrier, and an outlet in communication with said chamber. Methods of controlling moisture flow are also described.Type: ApplicationFiled: November 20, 2002Publication date: July 31, 2003Inventors: Anthony James Taylor, Michael Harry Golden
-
Publication number: 20030143163Abstract: This invention relates to aerosol formulations of use for the administration of medicaments by inhalation, in particular a pharmaceutical aerosol formulation which comprises particulate salbutamol and physiologically acceptable salts and solvates thereof and a fluorocarbon or hydrogen-containing chlorofluorocarbon propellant, which formulation is substantially free of surfactant. A method of treating respiratory disorders which comprises administration by inhalation of an effective amount of a pharmaceutical aerosol formulation as defined is also described.Type: ApplicationFiled: March 11, 2003Publication date: July 31, 2003Applicant: Glaxo Group LimitedInventors: Rachel Ann Akehurst, Anthony James Taylor, David Andrew Wyatt
-
Publication number: 20030010337Abstract: There is provided a dispenser comprising a body for receipt of a carrier for a composition; an exit channel definable by the body for passage of the composition to a user; a cover for the exit channel reversibly movable between a storage position in which the cover fully protects the exit channel, to an in-use position wherein the exit channel is exposed. Biasing means act on the cover when the cover is not in the in-use or storage positions, to bias the cover towards either the in-use position or the storage position.Type: ApplicationFiled: June 24, 2002Publication date: January 16, 2003Inventors: Gregor John McLennan Anderson, Anthony James Taylor
-
Patent number: 6410609Abstract: The invention described herein pertain generally to at least semi-rigid polyurethane foams which cure upon exposure to moisture and which contain major amounts of non-ozone depleting hydrofluorocarbon gas. The foams additionally contain a diisocyanate, preferably, 4,4′-diphenylmethane diusocyanate (MDI) and optionally including higher oligomers of MDI (polymeric MDI) in addition to at least two polyols of different molecular weights, e.g., as measured by number average molecular weight, preferably a polyester or polyether polyol, more preferably a polyalkylene polyol. The at least two polyols have a difference in molecular weight which is greater than or equal to 10%, preferably greater than or equal to 20%, more preferably greater than or equal to 35%, and most preferably greater than or equal to 50%, said number average molecular weight of the higher molecular weight polyol being no greater than approximately 4,000.Type: GrantFiled: July 27, 2000Date of Patent: June 25, 2002Assignee: Fomo Products, Inc.Inventors: Anthony James Taylor, Reto Faessler
-
Publication number: 20020058011Abstract: A pharmaceutical aerosol formulation comprising (i) particulate medicament, (ii) 1,1,1,2-tetrafluoroethane, 1,1,1,2,3,3,3,-heptafluoro-n-propane or a mixture thereof as propellant, and (iii) 0.01 to 5% w/w based upon the propellant of a polar cosolvent, the particulate medicament being present in an amount from 0.005% to 5% w/w relative to the total weight of the formulation and having a particle size of less than 100 microns, and which formulation contains less than 0.0001% w/w surfactant based upon the weight of medicament.Type: ApplicationFiled: November 8, 2001Publication date: May 16, 2002Applicant: Glaxo Group LimitedInventors: Rachel Ann Akehurst, Anthony James Taylor, David Andrew Wyatt
-
Publication number: 20020031479Abstract: A pharmaceutical formulation comprising (i) one or more particulate medicaments, and (ii) 1,1,1,2-tetrafuoroethane as propellant, which formulation contains less than 0.0001% w/w surfactant based upon the weight of medicament, particulate medicament being present in an amount from 00005 to 5% w/w relative to the total weight of the formulation and having a particle size of less than 100 micrions, with the proviso that said medicament is other than salmeterol, salbutamol, fluticasone propionate, beclomethasone dipropionate or a physiologically acceptable salt or solvate thereof and with the proviso that when said formulation consists of betamethasone, ergotamine tartrate or sodium cromoglycate and 1,1,1,2-tetrafluoroethane the weight to weight ratio of medicament to propellant is other than 69:7900 or 0.866% w/w.Type: ApplicationFiled: September 4, 2001Publication date: March 14, 2002Applicant: Glaxo Group LimitedInventors: Rachel Ann Akehurst, Anthony James Taylor, David Andrew Wyatt
-
Publication number: 20020028183Abstract: This invention relates to aerosol formulations of use for the administration of medicaments by inhalation, in particular a pharmaceutical aerosol formulation which comprises particulate salbutamol and physiologically acceptable salts and solvates thereof and a fluorocarbon or hydrogen-containing chlorofluorocarbon propellant, which formulation is substantially free of surfactant. A method of treating respiratory disorders which comprises administration by inhalation of an effective amount of a pharmaceutical aerosol formulation as defined is also described.Type: ApplicationFiled: June 21, 2001Publication date: March 7, 2002Applicant: Glaxo Group LimitedInventors: Rachel Ann Akehurst, Anthony James Taylor, David Andrew Wyatt
-
Patent number: 6333023Abstract: A pharmaceutical aerosol formulation comprising (i) particulate medicament, (ii) 1,1,1,2-tetrafluoroethane, 1,1,1,2,3,3,3,-heptafluoro-n-propane or a mixture thereof as propellant, and (iii) 0.01 to 5% w/w based upon the propellant of a polar cosolvent, the particulate medicament being present in an amount from 0.005% to 5% w/w relative to the total weight of the formulation and having a particle size of less than 100 microns, and which formulation contains less than 0.0001% w/w surfactant based upon the weight of medicament.Type: GrantFiled: May 1, 2000Date of Patent: December 25, 2001Assignee: Glaxo Group LimitedInventors: Rachel Ann Akehurst, Anthony James Taylor, David Andrew Wyatt
-
Patent number: 6306369Abstract: A pharmaceutical formulation comprising (i) one or more particulate medicaments, and (ii) 1,1,1,2-tetrafluoroethane as propellant, which formulation contains less than 0.0001% w/w surfactant based upon the weight of medicament, particulate medicament being present in an amount from 0.005 to 5% w/w relative to the total weight of the formulation and having a particle size of less than 100 microns, with the proviso that said medicament is other than salmeterol, salbutamol, fluticasone propionate, beclomethasone dipropionate or a physiologically acceptable salt or solvate thereof and with the proviso that when said formulation consists of betamethasone, ergotamine tartrate or sodium cromoglycate and 1,1,1,2-tetrafluoroethane the weight to weight ratio of medicament to propellant is other than 69:7900 or 0.866% w/w.Type: GrantFiled: April 28, 2000Date of Patent: October 23, 2001Assignee: Glaxo Group LimitedInventors: Rachel Ann Akehurst, Anthony James Taylor, David Andrew Wyatt